Kazia Therapeutics Limited Adr stock is traded at $7.35, with a volume of 64,621. It is up +5.00% in the last 24 hours and down -20.63% over the past month. Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Previous Close:
$7.00
Open:
$7.01
24h Volume:
64,621
Relative Volume:
0.36
Market Cap:
$114.28M
Revenue:
$26,600
Net Income/Loss:
-$14.73M
P/E Ratio:
-
EPS:
-$6.82
Net Cash Flow:
-$8.76M
1W Performance:
-13.53%
1M Performance:
-20.63%
6M Performance:
-46.89%
1Y Performance:
-2.00%
1-Day Range:
$6.89$7.47
1-Week Range:
$6.89$8.75
52-Week Range:
$4.86$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Name
Kazia Therapeutics Limited AdrSector
HealthcareIndustry
BiotechnologyPhone
01161298780088Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW, AustraliaMarket Cap
Revenue
Net Income
Cash Flow
EPS